Pharmacogenetics and Genomics · 2006 · 374 citations · 31 references
MedicinePharmacokineticsPharmacologyMedical GeneticsPharmacogeneticsPharmacogenomicsAnticoagulation TherapyGenotype-phenotype Association AnalysisPharmacogenetic TestingPopulation PharmacogeneticsPopulation PharmacogenomicsCyp2c9 GenotypingGenetic PolymorphismsGenetic Variability AnalysisIntra-subject VariabilityPharmacodynamic MechanismsPharmacodynamic VariantsVkorc1 GenotypeVkorc1 Genotyping
OBJECTIVE: To investigate pharmacokinetic and pharmacodynamic factors associated with population differences in warfarin doses needed to achieve anticoagulation, in particular the possible involvement of genetic variability in vitamin K epoxide reductase (VKOR) and CYP2C9. METHODS: Warfarin maintenance dose, unbound plasma S-warfarin concentration [Cu(S)] and INR were determined in 157 Caucasians, 172 Japanese, and 36 African-Americans stably anticoagulated patients. In a subset (n = 166), fully carboxylated plasma normal prothrombin levels (NPT) were also measured. Genotyping for seven CYP2C9 (CYP2C9*1 through 6 and *11) and seven VKORC1 variants were performed in 115 Caucasians and 64 Japanese patients and 66 healthy African-Americans. Multivariate analysis was performed to identify covariates associated with warfarin requirement. RESULTS: The relationship between NPT and Cu(S) indicated Japanese are more susceptible to inhibition of NPT production by S-warfarin than the other two populations. VKORC1 1173 C > T had a greater frequency in Japanese (89.1%) than Caucasians (42.2%) and African-Americans (8.6%). CYP2C9 variants with reduced metabolizing ability were less frequent in Japanese compared to the other two populations. The median warfarin dose was significantly higher in Caucasians than Japanese patients (5.5 versus 3.5 mg/day), however, when matched for CYP2C9*1 homozygosity, no difference in dose was observed between VKORC1 genotype-matched groups. Furthermore, VKORC1 1173C > T and CYP2C9 (*2/*3/*11) genotypes, age and weight were identified as independent covariates contributing to interpatient variability in warfarin dosage. CONCLUSIONS: Both VKORC1 and CYP2C9 polymorphisms contribute to inter-population difference in warfarin doses among the three populations, but their contribution to intra-population variability may differ within each population.
31
The Pharmacology and Management of the Vitamin K Antagonists
Jack Ansell, Jack Hirsh, L. Poller et al. · CHEST Journal · 2004 · 1.5K citations
Effect of <i>VKORC1</i> Haplotypes on Transcriptional Regulation and Warfarin Dose
Mark J. Rieder, Alex P. Reiner, Brian F. Gage et al. · New England Journal of Medicine · 2005 · 1.4K citations · Full text
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Simone Rost, Andreas Fregin, Vytautas Ivaškevičius et al. · Nature · 2004 · 1.1K citations